priors.science/reviews/inflammatory-bowel-disease

Inflammatory Bowel Disease

The current evidence on 23 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

23claims tracked
248primary papers reviewed
6 Jul 2026latest evidence review
Weeklyre-scored against new papers
5 Established · 12 Likely · 6 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableAnti-TNF induces remission in Crohn's diseaseAnti TNFEstablished94%20
StableUstekinumab achieves remission in Crohn's diseaseUstekinumabEstablished93%15
StableTofacitinib effective in moderate-to-severe ulcerative colitisJAKEstablished92%10
StableCombination anti-TNF plus immunomodulator beats monotherapyAnti TNFEstablished90%13
StableSubcutaneous vedolizumab non-inferior to intravenous in ulcerative colitisVedolizumabEstablished88%8
StableUpadacitinib induces and maintains remission in Crohn's diseaseJAKLikely82%9
StableJAK inhibitors increase herpes zoster riskJAKLikely80%10
StableVedolizumab superior to adalimumab in ulcerative colitisVedolizumabLikely80%16
StableMirikizumab induces and maintains ulcerative colitis remissionIl23Likely79%8
StableMucosal healing reduces inflammatory bowel disease complicationsTreatment TargetsLikely79%10
StableUstekinumab non-inferior to adalimumab in Crohn's diseaseUstekinumabLikely79%13
StableRisankizumab superior to ustekinumab in Crohn's diseaseIl23Likely78%9
StableCalprotectin predicts mucosal healingTreatment TargetsLikely77%10
StableRisankizumab induces and maintains ulcerative colitis remissionIl23Likely75%8
StableMirikizumab achieves remission in Crohn's diseaseIl23Likely74%7
StableVedolizumab effective in anti-TNF-failure Crohn's diseaseVedolizumabLikely74%13
StableTherapeutic drug monitoring improves anti-TNF loss-of-response outcomesAnti TNFLikely70%13
StableTop-down anti-TNF improves Crohn's disease outcomesAnti TNFUncertain58%10
StableTransmural healing superior target in Crohn's diseaseTreatment TargetsUncertain56%10
StableUstekinumab better than vedolizumab in anti-TNF-failure Crohn's diseaseUstekinumabUncertain55%12
StableUpadacitinib superior to vedolizumab in ulcerative colitisPositioningUncertain54%7
StableUpadacitinib superior to tofacitinib in ulcerative colitisJAKUncertain52%9
StableIL-23 inhibitors safer than JAK inhibitorsPositioningUncertain50%8
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic